Navigation Links
New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
Date:5/23/2014

A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated in a phase I study.

The drug, alisertib or MLN8237, inhibits the enzyme aurora A kinase, which is known to be very active during cell division. The present study, published in the journal Investigational New Drugs, looks at the safety, tolerability, and preliminary success of alisertib in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

"An advantage with this drug is it is oral and very effective in a significant number of patients with aggressive lymphoma when used at that dose for 7 days out a 21 day cycle," said hematologist Swaminathan Iyer, M.D., who led the multi-site study.

Drugs commonly used to treat NHL and CLL are chemotherapeutic drugs and some biological targeted agents such as the monoclonal antibodies rituximab, ofatumumab and obinutuzumab with varying degrees of success.

Although about 1/2 of patients participating in the phase I study experienced side effects most of which were manageable events, Iyer said that is not unusual for such biologic (non chemotherapy) drugs.

"The side effects were fairly tolerable in this study," Iyer said. "We would like to see more information from a larger group of patients to fully understand the drug's safety and tolerability for those experiencing the middle-to-later stages of these diseases."

Iyer and his group recommend 50 mg, twice-daily doses of alisertib for the advanced phase trials of the drug, which Iyer says has begun enrollment.

Alisertib is not yet approved for general medical use by the FDA. Its impact on T cell lymphoma is being investigated in a separate, phase III trial for a specific type of lymphoma called the T cell lymphomas. Houston Methodist is a participating study site for that project. Initial phase II reports in these T cell lymphomas showed a 57% response, the highest ever noted for any single agent in this disease entity.


'/>"/>

Contact: David Bricker
dmbricker@houstonmethodist.org
832-667-5811
Houston Methodist
Source:Eurekalert

Related medicine news :

1. Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
2. Novel drug therapy targets aggressive form of non-Hodgkins lymphoma
3. International symposium will address non-Hodgkins lymphoma in the young
4. Inhibition of CDK4 might promote lymphoma development and progression
5. Increased risk of relapse omitting RT in early PET scan negative Hodgkin lymphoma
6. Chemo-free treatment a possibility for leukemia/lymphoma
7. Scientists explore promising new option for first line of attack in lymphoma
8. Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells
9. MedMar Healing Center Co-founder Rafael Hernandez Goes the Distance for Leukemia and Lymphoma Society, Running Three Marathons for Nonprofit Health Organization
10. Research shows genetic anti-inflammatory defect predisposes children to lymphoma
11. Reprogrammed treatment-resistant lymphomas respond to cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been paid to ... become dependent on opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses ... increase in fatal overdoses in male populations.(1) , The proportion of women using illicit ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health ... British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition ... Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol treatment ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, ... awareness and concern over nerve agents and the deadly use of chemical weapons. Many ... system and how even small doses can be lethal. , Jay Jagannathan, M.D., of ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC ... North America, today announced it would be offering some it’s exclusive product line ... on crafting quality and unique baby clothing/feeding products, will team up with AMAZON ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Global Empty Capsules Market is poised to grow at a ... billion by 2025. This industry report analyzes the market ... as regional levels presented in the research scope. The study provides historical ...
(Date:2/24/2017)... -- Physician General Dr. Rachel Levine and ... Smith commended South Central EMS today for their ... a life-saving overdose reversal drug. The recognition event also ... overdose survivor who was saved due to the administration ... part of fighting the opioid epidemic is making sure ...
(Date:2/24/2017)... , Feb. 24, 2017 Juan Monteverde ... Associates PC , a boutique securities firm headquartered at ... City , announces that a class action lawsuit ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" ... Company,s securities between July 23, 2015 and December 30, 2016, ...
Breaking Medicine Technology: